Otonomy (OTIC) to Present OTIPRIO Phase 2 Data in AOE at American Academy of Otolaryngology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Otonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
September 13, 2016 7:30 AM EDTSAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the upcoming presentation of results from an OTIPRIO® (ciprofloxacin otic suspension) Phase 2 trial in acute otitis externa (AOE), a potential label expansion indication, as well as the companys sponsorship of a symposium related to OTIPRIO during the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) to be held September 18-21, 2016 in San Diego.
... More
